Firm aims to introduce to the market a new generation coronary shunt for use during coronary artery bypass grafting surgery (CABG). CorFlow technology is being developed with several technological innovations increasing safety for the patients and facilitating shunt use by cardiac surgeons. Next generation coronary shunt is dedicated to improve the results of coronary artery bypass grafting and expand global number of less invasive CABG technique – beating heart, off-pump coronary artery bypass grafting (OPCAB).
Firm is conducted by physicians, including cardiac surgeon, specialists in medical devices designing, engineers, specialist of computational fluid dynamic modeling and managers experienced in med-tech sector and technology transfer to global markets.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Poleczki Street 19, Warsaw,poland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.corflowmed.com
- Keywords
- Athens.
- HQ
- Warsaw
Corflow Questions
Corflow's website is http://www.corflowmed.com
Corflow's LinkedIn profile is https://pl.linkedin.com/company/corflowmed
Corflow has
2 employees.
View email and phone details for 2
employees at Corflow.
Corflow's industry is
Biotechnology Research
Corflow's top competitors are
Heart Guard,
Medtech Holding Sp. Z O.o.,
Vastmed, Llc,
Carolina Medical Center,
Corflow,
Temed Ltd,
Heart Sense,
Smd Group,
Quantum Innovations,
Hellenic Association Of Endoscopic Surgery.
Corflow's categories are Biotechnology Research
Corflow's founding year is 2023
